Jide Zeitlin - Vascular Biogenics Non-Executive Independent Director

VBLTDelisted Stock  USD 0.16  0.01  5.88%   

Director

Mr. Jide James Zeitlin serves as NonExecutive Director at Vascular Biogenics Ltd since March 2008. He is a member of the Compensation committee. His work experience includes the following roles President of The Keffi Group Ltd, Chairman of Coach, Inc, Partner at the Goldman Sachs Group, Inc., where he held senior management roles in the investment banking division, including Global Chief Operating Officer, Chairman Emeritus of Amherst College, Chairman of the Investment Committee of the Nigeria Sovereign Investment Authority, Member of the boards of Affiliated Managers Group, Inc., Milton Academy, the Harvard Business School Board of Deans Advisors, Teach for America, Doris Duke Charitable Foundation, Montefiore Medical Center, Playwrights Horizons, Saint Anns School, and Common Ground Community since 2008.
Age 52
Tenure 16 years
Professional MarksMBA
Phone972 8 993 5000
Webhttps://www.vblrx.com
Zeitlin holds a Bachelors degree in Economics and English from Amherst College and a MBA degree from Harvard University.

Jide Zeitlin Latest Insider Activity

Tracking and analyzing the buying and selling activities of Jide Zeitlin against Vascular Biogenics stock is an integral part of due diligence when investing in Vascular Biogenics. Jide Zeitlin insider activity provides valuable insight into whether Vascular Biogenics is net buyers or sellers over its current business cycle. Note, Vascular Biogenics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vascular Biogenics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Vascular Biogenics Management Efficiency

The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vascular Biogenics until it has trouble settling it off, either with new capital or with free cash flow. So, Vascular Biogenics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vascular Biogenics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vascular to invest in growth at high rates of return. When we think about Vascular Biogenics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

BertJaap DijkstraSBM Offshore NV
50
Michal VotrubaMYnd Analytics
52
John PappajohnMYnd Analytics
89
Lu LuSunlands Technology Group
34
Wuhui ZhaoJutal Offshore Oil
49
Gaoneng JiSunlands Technology Group
31
Andrew SassineMYnd Analytics
51
James BurkeLincoln Educational Services
63
Danforth LeitnerVisionary Education Technology
78
Sam SunSunlands Technology Group
44
Harvey EadsVisionary Education Technology
73
Geoffrey HarrisMYnd Analytics
55
Yang WangSunlands Technology Group
45
Peter UnanueMYnd Analytics
50
David BicksVisionary Education Technology
86
Yimin ZhengJutal Offshore Oil
54
Yang SuJutal Offshore Oil
46
John FazziniVisionary Education Technology
75
Yunian LiJutal Offshore Oil
55
Zheng ZhaoSunlands Technology Group
41
Sergey BorovskiyJutal Offshore Oil
44
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Vascular Biogenics (VBLT) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Vascular Biogenics Leadership Team

Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dror Harats, CEO, Director
Amos Ron, CFO
Samuel Backenroth, Chief Officer
Bennett Shapiro, Non-Executive Independent Chairman of the Board
Naamit Sher, VP of Devel. and Regulatory
Ayelet Horn, General Counsel, Company Secretary
Philip Serlin, Non-Executive Independent Director
Dan Gelvan, Non-Executive Independent Director
Eyal Breitbart, Vice President Research
Ron Cohen, Non-Executive Independent Director
Pr MD, CEO Director
Tami MD, VP Devel
Ruth Alon, Non-Executive Independent Director
Erez Feige, Vice President - Business Operations
Ruth Arnon, Non-Executive Independent Director
Yael Cohen, Vice President - Clinical Development
Erez MBA, Sr Operations
Jacob George, Chief Scientific Officer
Jecheskiel Gonczarowski, Non-Executive Independent Director
Deborah Scott, Managing Communications
Jide Zeitlin, Non-Executive Independent Director
Advocate Horn, G Counsel

Vascular Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vascular Biogenics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vascular Biogenics' short interest history, or implied volatility extrapolated from Vascular Biogenics options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Equity Valuation
Check real value of public entities based on technical and fundamental data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world